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Research in context  
 
Evidence before this study  
End-stage kidney disease is a life-threatening complication of type 1 diabetes. Although, the 
incidence of end-stage kidney disease has decreased over the last decades, the decline is 
substantially lower in comparison with other common diabetes-related complications such as 
cardiovascular disease. Fortunately, end-stage kidney disease can be prevented or delayed by 
intervention, and early detection of persons at increased risk is essential. We searched 
PubMed for research articles published up to September 30, 2020 and selected key evidence. 
There are currently no risk prediction models developed specifically for end-stage kidney 
disease in type 1 diabetes. 
 
Added value of this study  
We have derived and validated a novel, high-performing prediction model for assessing risk 
of end-stage kidney disease in adults with type 1 diabetes. The model includes information 
that are routinely collected from clinical examinations. 
 
Implications of all the available evidence  
The prediction model showed excellent performance both internally and externally, 
indicating high usability in clinical practice. This model may improve clinical decision 





Background End-stage kidney disease (ESKD) is a life-threatening complication of type 1 
diabetes (T1D) which can be prevented or delayed by intervention. Hence, early detection of 
persons at increased risk is essential. 
 
Methods From a population-based cohort of 5,460 clinically diagnosed Danish adults with 
T1D followed 2001-2016, we developed a prediction model for ESKD accounting for the 
competing risk of death. Poisson regression analysis was used to estimate the model based on 
information routinely collected from clinical examinations. The effect of including an extended 
set of predictors (lipids, alcohol intake etc.) was further evaluated, and potential interactions 
identified in a survival tree analysis were tested. The final model was externally validated in 
9,175 T1D adults from Denmark and Scotland. 
 
Findings During a median follow-up of 10∙4 years (interquartile limits: 5∙1;14∙7), 303 (5∙5%) 
of the participants (mean (SD) age 42∙3 (16∙5) years) developed ESKD and 764 (14∙0%) died 
without having developed ESKD. The final ESKD prediction model included age, male sex, 
diabetes duration, estimated glomerular filtration rate, micro- and macroalbuminuria, systolic 
blood pressure, HbA1c, smoking and previous cardiovascular disease. Discrimination was 
excellent for 5-year risk of ESKD event with a C-statistic of 0∙888 (95%CI: 0∙849;0∙927) in the 
derivation cohort and confirmed at 0∙865 (0∙811;0∙919) and 0∙961 (0∙940;0∙981) in the external 
validation cohorts from Denmark and Scotland.  
 
Interpretation We have derived and validated a novel, high-performing ESKD prediction 
model for risk stratification in the adult T1D population. This model may improve clinical 










The observed incidence of end-stage kidney disease (ESKD) in persons with type 1 diabetes 
(T1D) has stabilised1 or decreased over the last decades,2-4 probably related to the increased 
use of renin-angiotensin system (RAS) blockers. However, the decline in ESKD risk has been 
substantially lower in comparison with other common diabetes-related complications such as 
cardiovascular disease,1,5 and ESKD still remains a life-threatening complication6 with a 10-
fold increase in mortality rate in T1D.3  
 
Fortunately, ESKD can be prevented or delayed by intensive glucose- and blood pressure 
lowering therapy,7 and early detection is therefore essential. ESKD often develops in persons 
with complicated and poorly controlled T1D.6 This group also face a high degree of pre-ESKD 
death, especially in the older ages.3 Because death precludes the occurrence of ESKD, a 
person’s risk of developing ESKD also depends on overall mortality risk. Not considering the 
“competing” risk of death is likely to overestimate the absolute risk of ESKD.8,9 Because the 
decision to initiate ESKD preventive treatment is often based on the absolute risk of developing 
ESKD, it is essential to estimate individual ESKD risk accurately. 
 
Prediction models for ESKD in diabetes are scarce. Except for one study using a composite 
outcome of end-stage renal failure, coronary heart disease, stroke, amputations, blindness and 
death,10 and one study predicting renal function decline,2 there is, to our knowledge, no ESKD 
risk models developed for the T1D population. Three prediction models have been developed 
for cohorts of people with T2D, one in New Zealand11 and two in Chinese adults.12,13 T1D 
differs from T2D, in that persons with T1D are generally diagnosed at younger ages and 
therefore exposed to diabetes-related risk factors for ESKD, such as hyperglycaemia and 




disease and smoking appear to be risk factors for ESKD in both types of diabetes, obesity seems 
to play a larger role in T2D,14 whereas age at diabetes diagnosis is mainly a risk factor in 
T1D.3,14,15 This suggests a difference in the pathophysiology of ESKD for T1D and T2D, and 
prediction models specific to the T1D population are needed. 
 
Change in eGFR is a predictor of ESKD in diabetes,2 and the KDOQI Clinical Practice 
Guidelines for diabetes and CKD suggest monitoring the rate of decline in eGFR to predict the 
time to onset of kidney failure.16 However, information on prior eGFR trajectory in persons 
with T1D requires continuous monitoring of eGFR which is not widely feasible. Hence, the 
ability to assess ESKD risk in T1D based on current levels of risk factors is needed. 
 
The aim of this study was to develop a risk prediction model for ESKD accounting for the 
competing risk of death, using a large population-representative cohort of adults with T1D with 
an extensive range of clinical data and information on ESKD events and mortality from 
national registers. We externally validated the model in national and international cohorts to 
assess its broader generalisability. 
 
Methods  
Study design and data sources 
The study is based on a large population-based cohort of 5,506 adults T1D treated at the 
outpatient clinic at Steno Diabetes Center Copenhagen (SDCC) in the period from  January 1st, 
2001 to  December 31st, 2016. In Denmark, treatment of persons with T1D is based in tertiary 
care and referral to specialist care is free of charge. The T1D population at SDCC includes the 
entire adult age span with both newly diagnosed and long-term diabetes, reflecting the 




of their first clinical examination with a measurement of serum creatinine until first event of 
ESKD, death, emigration, or until censor date  December 31st, 2016 (date of register 
extraction). 
 
To ensure exclusion of extreme values of metabolic risk factors such as haemoglobin A1c 
(HbA1c) and lipids often present at the time of diagnosis, clinical examinations within the first 
year of diabetes diagnosis were excluded from the analyses. We further excluded persons with 
prevalent ESKD at their first clinical examination (n = 46 (0∙8%)), leaving 5,460 persons with 
T1D with a total of 42,921 clinical examinations for analysis.  
 
According to Danish law, ethics approval and participant consent is not required for registry-
based studies. Access and use of the described data were approved by the Danish Data 
Protection Agency (j-No: VD-2019-197) and the Danish Patient Safety Authority (j-No: 3-
3013-2959/1). 
 
Outcome and exposures 
Detailed clinical data of the participants were collected from the electronic health records at 
SDCC and linked to nationwide registries on mortality and morbidity including ESKD,17,18 
using the unique personal identification number given to all Danish residents at birth or at 
immigration.19  
 
Clinical data from the electronic health records 
To separate diabetes type 1 from type 2, T1D was clinically diagnosed based on phenotype and 





Electronic health data on all clinical visits with a measurement of serum creatinine were 
extracted together with the corresponding clinical- and behavioural data. Detailed information 
on how measurements were obtained have been reported previously20,21.   
 
Albuminuria was classified from 24-hour sterile urine collections (mg/24h) or spot urine 
(mg/g) into normoalbuminuria (<30), microalbuminuria (30-299) or macroalbuminuria (≥ 
300). We categorised smoking status into current smoking (yes/no), physical activity into 
regular physical activity defined as ≥ 30 minutes per day (yes/no), alcohol intake in three 
classes (0, 1–20, and >20 units/week), use of antihypertensive treatment (yes/no), lipid-
lowering treatment (yes/no), and RAS blocking treatment (yes/no). Retinopathy status was 
assessed from retinal photographs (no retinopathy, mild/moderate retinopathy or severe 
retinopathy). Estimated glomerular filtration rate (eGFR) was calculated using the Chronic 
Kidney Disease (CKD) Epidemiology Collaboration equation. (see supplemental material for 
further details).  
 
Data from national registries 
Previous CVD was defined as any previous event of ischemic heart disease, ischemic stroke, 
heart failure, and peripheral artery disease as previously defined.21 We defined ESKD as a 
composite event of CKD stage 5 (ICD-10 code DN185), dialysis (procedure code BJFD), 
kidney transplantation (procedure code KKAS) or an eGFR <15 mL/min/1∙73m2. ESKD event 
data was obtained from the Danish National Patient Register.18 Data on date and cause of death 
was collected from the Cause of Death Register.17 Death without having developed ESKD was 
defined as non-ESKD related mortality. Data on ethnicity were obtained from the Central 








To account for the competing risk of death, cause-specific rate models for ESKD and death 
were estimated and then combined into a model for cumulative ESKD risk using the 
conditional survival function.8  
 
We first developed a core model from commonly measured factors including age, sex, diabetes 
duration, eGFR, albuminuria status, systolic- and diastolic blood pressure, HbA1c, smoking and 
previous CVD, and an extended model which further included RAS blocking treatment, other 
antihypertensive treatment, lipid-lowering treatment, BMI, ethnicity, retinopathy, total- and 
HDL cholesterol, LDL cholesterol, triglycerides, haemoglobin, alcohol intake, regular 
exercise, height, urinary albumin-to-creatinine ratio (UACR), potassium, sodium, TSH. 
Predefined interactions between clinical measurements and treatment, as well as other 
interactions between predictors identified in a prior conditional survival trees analysis were 
included in both models. 
 
In a subset of 4,815 (88%) participants with at least two clinical examinations, we further tested 
the effect of including eGFR annual change prior to baseline in the core model.  
 
The cause-specific rate models for ESKD and death were estimated separately using Poisson 
models with log of the risk time as offset and censoring for the other event. For each participant, 
the follow-up period was split into 1-year age bands and further at the time points of repeated 




predictors were used, and age and diabetes duration were updated. Before analysis, predictors 
with a highly skewed distribution were log2-transformed to improve model calibration. 
Backwards elimination was used to test the predictors and interactions. The level of statistical 
significance was set at 5%. 
 
Post-estimation shrinkage factors for the predictors were estimated in all the cause-specific rate 
models.22 
 
The discriminatory power of the models was evaluated using the C-statistic23 with confidence 
interval computed from the DeLong method. In addition, model calibration was determined 
with Hosmer-Lemeshow test of goodness of fit24 by comparing means of estimated cumulative 
ESKD risk with the corresponding observed incidence in deciles of estimated risk.  
 
Multivariate imputations by chained equations was used to impute missing values and 
estimates summarised according to Rubin’s rules. Details of the statistical analysis are supplied 
in the supplemental material.   
 
Validation 
The cumulative incidence functions for ESKD with the original regression coefficients in both 
the core- and extended models were internally validated using the first clinical examination of 
the derivation cohort. 
 
The cumulative incidence function for ESKD with both the original and the shrunken 
regression coefficients for the core model was externally validated nationally in the T1D 




Diabetes Research Network Type 1 Bioresource (SDRNT1BIO)2. The validation cohorts did 
not have the required data available for validation of the extended model.  
 
In FDDB, where we had access to baseline eGFR, discrimination and model calibrations for a 
5-year and 10-year ESKD event among participants with eGFR ≥60 mL/min/1∙73m2 at baseline 
was also calculated. This subgroup constituted 91% of the FDDB study participants but 
accounted for only 41% and 46% of the ESKD events after 5- and 10 years of follow-up. 
 
Statistical analyses were performed in R version 3∙6∙1 (The R Foundation for Statistical 
Computing, http://www.r-project.org/).  
 
Role of the funding source 
There was no funding source for this study. The corresponding author had full access to all the 
data in the derivation cohort and to part of the data in the validation cohorts, and had final 




The derivation cohort was mainly (91%) of European origin. Baseline characteristics are given 
in Table 1. At baseline, 7% had CKD stage 3 or 4 and 37% developed ESKD during follow-
up. The majority of the ESKD cases were among participants with an eGFR ≥60 
mL/min/1∙73m2 (Supplemental Table S1). This group was characterised by a high degree of 
micro- or macroalbuminuria (45% vs 19% in the total cohort). Participants were followed for 




ESKD and 764 (14∙0%) died of non-ESKD related causes without having developed ESKD. 
The incidence rate of ESKD was 5∙7 per 1000 person-years.  
  
The final core model for cumulative risk of ESKD included age, sex, diabetes duration, eGFR, 
micro- and macroalbuminuria, systolic blood pressure, HbA1c, smoking and previous CVD. 
Older age was associated with a lower rate of ESKD but with a higher rate of mortality. For 
the remaining predictors, more unfavourable levels were associated higher rates of both ESKD 
and death (Table 2). In the extended model, increasing levels of haemoglobin and 
mild/moderate retinopathy was associated with a higher rate of ESKD but a lower rate of death. 
Higher levels of UACR was further associated with higher risk of ESKD and death. BMI, 
triglycerides, regular exercise and sodium was associated with the rate of mortality and thereby 
indirectly associated with the cumulative risk of ESKD (Supplemental Table S2). Overall, the 
results of the survival tree analyses were consistent with the difference in baseline 
characteristics between individuals who do and do not develop ESKD (Supplemental Table S1 
and Figures S1-S4). 
 
The estimated impact of calendar time was small (< 2% difference in incidence rate per 
calendar year) and was not statistically significant (P ≥ 0∙241 for ESKD, P ≥ 0∙066 for death). 
Hence, calendar time was not included.  
 
The core model showed excellent and robust discrimination with C-statistics of 0∙872 and 
above over the 10 years of follow-up in the derivation data. Model calibration was good for up 
to five years. The extended model had slightly better performance with C-statistics of 0∙883 
and above and good calibration for up to six years (Figure 1 and Supplemental Table S3). 
Details on the estimated model parameters with- and without post-estimation shrinkage and 





In the sensitivity analysis, including pre-baseline change in eGFR in the core model had little 
effect with an incidence rate ratio below 1% for a 10-unit difference in eGFR change (P = 
0∙078). Also, discrimination for a 5- and 10-year ESKD event was not improved (P ≥ 0∙290) 
and model calibration was unchanged. 
 
Validation cohorts 
The Danish FDDB cohort of 3,150 adults were followed between  January 1st, 2003 to  
December 31st, 2016 and was representative of the T1D population in that region. They were 
on average five years older at diabetes diagnosis, macroalbuminuria and severe retinopathy 
was less frequent and current smoking was around half of that in the derivation cohort (Table 
1). Median (IQR) years of follow-up was 10∙7 (5∙8; 13∙6) during which 147 (4∙7%) developed 
ESKD and 422 (13∙3%) died from non-ESKD causes, corresponding to an incidence rate of 
ESKD of 4∙9 per 1000 person-years. The core model without shrinkage of the parameters 
performed best. Discrimination was excellent and robust over time with a C-statistic of 0∙871 
for an ESKD event within 5 years and 0∙866 for an event within 10 years. Model calibration 
was good for up to 5-6 years of follow-up (Figure 1 and Supplemental Table S3). In the 
subgroup with baseline eGFR ≥60 mL/min/1∙73m2, C-statistic was 0∙744 (95%CI: 0∙641; 
0∙847) and 0∙775 (0∙711; 0∙840) for a 5-year and 10-year ESKD event. Model calibration was 
adequate (P ≥ 0∙097). 
 
The SDRNT1BIO cohort of 6,025 adults were followed between  January 1st, 2011 to  
December 31st, 2018 and was representative of the T1D population in Scotland. The 
SDRNT1BIO population was slighter older and with around five years longer diabetes duration 




less macroalbuminuria and severe retinopathy and the prevalence of current smoking was 
around half of that in the derivation cohort. The SDRNT1BIO population had almost twice as 
many using RAS blocking agents and with five times as many using lipid-lowering medications 
(Table 1). Median (IQR) follow-up was 6∙9 (6∙2;7∙4) years during which 95 (1∙6%) developed 
ESKD and 321 (5∙3%) died from non-ESKD causes, corresponding to an incidence rate of 
ESKD of 2∙4 per 1000 person-years (Table 1). The performance of the core model was similar 
with and without shrinkage of the parameters. For the model without shrinkage, discrimination 
was excellent and robust with a C-statistic of 0∙961 for an ESKD event within 5 years and 0∙952 
for an event within 8 years (the maximum follow-up time)∙ Calibration was only borderline 
acceptable the first 4-5 years for the core model (Figure 1 and Supplemental Table S3).  
 
Discussion 
We have derived and validated a high-performing model for predicting individual risk of ESKD 
in the adult T1D population based on predictors routinely collected in the clinic. An extension 
of the model to include less frequently measured factors did not substantially improve 
prediction, suggesting that the more parsimonious core model, which is more feasible in a 
clinical setting, is preferable for assessing individual 5-year ESKD risk in persons with T1D.  
 
The ESKD cumulative incidence rates in the Danish derivation- and validation cohort was 
twice that of the validation cohort from Scotland and considerable higher than previously 
reported in Sweden and Finland.3,26 The annual incidence rates in the derivation cohort only 
decreased slightly over the 2001-2016 follow-up period. The referral criteria for persons with 
T1D are comparable in Denmark and Scotland, and the selection criteria for the cohorts was 




50. A possible explanation for the difference in ESKD risk could be the more aggressive 
treatment with RAS blockers and a lower prevalence of smoking in Scotland. 
 
The predictors included in the core model have previously been found to be associated with 
ESKD.2-4,15 However, no studies have combined them into a model for predicting individual 
risk of ESKD in T1D. Only one model for ESKD has been developed in a population 
representative T2D cohort of mainly white ethnicity.11 When applied to our T1D population, 
we found discrimination to be adequate for a 5-year ESKD event (C-statistic: 0∙790 (0∙688; 
0∙893) but calibration was poor (P < 0∙001). 
 
Male sex was associated with increased risk of ESKD in our model which is in line with 
previous studies.3,15 A study from New Zealand found male sex to be associated with decreased 
risk of ESKD, but not when including eGFR in the model.11 The finding in a Swedish study of 
no risk difference in men and women diagnosed before puberty26 was not supported by the 
survival tree analysis in our study where no interaction between sex and age and diabetes 
duration was found.  
 
Although, ESKD is more frequent in old age,4,15 the rate of ESKD is decreasing with age in 
our model. This is likely due to a healthy survivor effect driven by the strong association 
between age and mortality. In other words, old age may seem protective of ESKD because old 
people die before they develop ESKD. This finding is in line with another competing risk 
analysis of ESKD risk in T1D who have macroalbuminuria and CKD stages 1–3.15  
 
RAS blocking agents and other antihypertensive treatment did not improve the models. Similar 




association of antihypertensive medication with ESKD was lost when eGFR was included in 
the model.4  
 
Some studies have shown a decline in ESKD incidence over time.3,4 However, calendar time 
was not associated with ESKD in our model, indicating that any observed decline in ESKD 
over the years is reflected in the change in risk factor levels.27 This is supported by the WESD 
study from the US where an observed decline in incidence of ESKD over time was explained 
by improvements in glycaemic- and blood pressure control.4 
 
Our core model is adequate for assessing 5-year risk of ESKD but predictions beyond this is 
questionable. Previous models have also primarily been assessed for 5-year risk of ESKD11,13 
although one model in T2D was well calibrated up to 8 years of follow-up.12  
  
Strengths and limitations 
We had access to detailed data from repeated clinical examinations for the study participants, 
which allowed us to update the values of the predictors during follow-up to give a more correct 
estimate of the associations between the predictors and the event. In addition, missing data was 
imputed, thereby removing selection bias.  
 
The derivation cohort was mainly of white ethnicity which may explain why ethnicity was not 
predictive in the models, and further validation in populations of non-White ethnicity is needed. 
 
Our models were developed based on data collected at a single clinical examination. Although, 




levels in T1D2 and ESKD in the general population,28 pre-baseline change in eGFR in addition 
to baseline eGFR level did not improve prediction of future ESKD in our study.  
 
In the future, prediction models for ESKD may also benefit from the inclusion of novel 
biomarkers or with various omics data. However, such biomarkers which are not used or 
collected routinely in clinical practice have yet to prove predictive beyond that of clinical data.  
 
Clinical perspective  
Although age-specific prevalence and incidence of ESKD have been stable since 2006 in 
Denmark,1 the actual number of T1D developing ESKD is increasing due to the general ageing 
of the population. Mortality is still 70% higher in T1D compared with T2D,29 and quality 
measures of diabetes care in Denmark indicate a less aggressive approach to manage 
cardiovascular risk factors in T1D.30 Early treatment could prevent or at least postpone the 
development of ESKD and hereby reduce treatment expenses and increase quality of life in 
T1D.  
 
Our prediction model was developed for the entire range of eGFR not within the ESKD 
diagnostic range. Although, persons with CKD stage 3 and 4 are likely already managed as a 
high-risk group, they will not all develop ESKD. In contrast, the majority of the ESKD events 
occurs among persons considered at low risk with baseline eGFR ≥60 mL/min/1∙73m2. Our 
model also performed well in this subpopulation, and we believe ESKD risk assessment is 






We have derived and validated a novel, high-performing ESKD prediction model for risk 
stratification in the adult T1D population. This model may improve clinical decision making 
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Table 1 Characteristics of the study populations at their first clinical examination in the 
derivation cohort and for the validation cohorts 
 Derivation cohort  Validation cohorts 
 SDCC  FDDB SDRNT1BIO 
N 5460  3150 6025 
Follow-up time (years) 10∙4 (5∙1;14∙7)  10∙7 (5∙8;13∙6) 6∙9 (6∙2;7∙4) 
Region of origin (%)     
European 91∙3  - - 
Middle East 6∙1  - - 
Other 2∙6  - - 
Age (years) 42∙3 (16∙5)  42∙8 (16∙7) 45∙1 (15∙0) 
Males (%) 54∙1  57∙8 56∙1 
Age at diabetes diagnosis (years) 21∙0 (12∙2;33∙8)  26∙1 (14∙3;40∙4) 21∙6 (12∙1;32∙2) 
Diabetes duration (years) 15∙6 (6∙6;27∙4)  10∙9 (2∙5;21∙9)  20∙3 (11∙0;30∙9) 
HbA1c (mmol/mol) 69∙4 (16∙7)  67∙0 (18∙8) 71∙1 (17∙0) 
HbA1c (%) 8∙5 (1∙5)  8∙3 (1∙7) 8∙7 (2∙0) 
BMI (kg/m2) 24∙7 (3∙7)  25∙2 (4∙3) 27∙1 (5∙0) 
UACR (mg/g) 8∙0 (4∙0;19∙0)  10∙6 (4∙5;26∙8)  8∙8 (5∙1;25∙7) 
Albuminuria (%)     
Normal 81∙0  76∙8 83∙1 
Micro 13∙0  19∙9 12∙6 
Macro 6∙0  3∙4 4∙3 
Serum creatinine (μmol/L) 82∙0 (69∙0;93∙0)  - - 
eGFR (mL/min/1∙73m2) 99∙8 (84∙3;114∙6)  89∙5 (75∙1;104∙2) 100∙0 (84∙3;111∙4) 
eGFR categories (%)     
eGFR ≥ 90 66∙6  49∙3 - 
60 ≤ eGFR < 90 26∙3  41∙8 - 
30 ≤ eGFR < 60 6∙0  8∙1 - 




Haemoglobin (mmol/L) 8∙7 (0∙8)  - - 
Potassium (mmol/L) 4∙0 (0∙4)  - - 
Sodium (mmol/L) 138∙8 (3∙0)  - - 
TSH (×10–3 IU/L) 1∙5 (0∙9;2∙2)  - - 
Systolic blood pressure (mmHg) 132∙1 (19∙2)  130∙9 (18∙3) 130∙8 (16∙0) 
Diastolic blood pressure (mmHg) 78∙0 (10∙0)  77∙7 (10∙5) 75∙4 (10∙0) 
Total cholesterol (mmol/L) 4∙9 (1∙0)  4∙9 (1∙0) - 
HDL cholesterol (mmol/L) 1∙6 (0∙5)  1∙7 (0∙5) 1∙5 (0∙5) 
LDL cholesterol (mmol/L) 2∙7 (0∙9)  2∙7 (0∙9) 2∙5 (1∙0) 
Triglycerides (mmol/L) 1∙0 (0∙7;1∙5)  1∙0 (0∙7;1∙5) 1∙1 (0∙8;1∙7) 
RAS blockers (%) 21∙6  8∙9 37∙3 
Other antihypertensive treatment (%) 26∙9  7∙1 28∙1 
Lipid-lowering medication (%) 10∙4  9∙3 52∙1 
Retinopathy status (%)     
No apparent retinopathy 46∙3  50∙1 38∙5 
Mild/moderate 22∙0  32∙5 34∙9 
Severe 31∙7  17∙5 26∙6 
Current smoking (%) 51∙3  27∙1 21∙9 
Alcohol intake (%)#     
0 units/week 14∙5  - 15∙2 
1-20 units/week 80∙6  - 71∙9 
> 20 units/week 4∙8  - 12∙8 
Regular exercise (%)† 69∙1  56∙7 40∙0 
Previous CVD (%) 8∙9  9∙4 6∙8 
Data are means (SD), medians (interquartile limits), or percentages.  
BMI: body mass index; eGFR: estimated glomerular filtration rate calculated using the Chronic Kidney Disease 
(CKD) Epidemiology Collaboration standard equation.; HbA1c: haemoglobin A1c; UACR: urinary albumin-to-
creatinine ratio; TSH: thyroid-stimulating hormone; HDL: high-density lipoprotein; LDL: low-density 
lipoprotein; CVD: Cardiovascular disease; ESKD: end-stage kidney disease.  




Table 2 Incidence Rate Ratios (IRR) for predictors of ESKD and death and postestimation 
shrinkage factors - core model 
 ESKD  Non-ESKD death 
  IRR (95%CI) P value  IRR (95%CI) P value 
Age (10 years) 0∙83 (0∙75;0∙92) <0∙001  - 
Male sex (vs female sex) 1∙40 (1∙11;1∙78) 0∙005  5∙47 (2∙58;11∙61) <0∙001 
Diabetes duration (10 years) 1∙13 (1∙02;1∙25) 0∙022  1∙11 (1∙05;1∙16) <0∙001 
eGFR (halving) 8∙15 (6∙88;9∙65) <0∙001  1∙28 (1∙11;1∙49) <0∙001 
Microalbuminuria (vs normoalbuminuria) 1∙09 (0∙76;1∙55) 0∙643  1∙64 (1∙39;1∙94) <0∙001 
Macroalbuminuria (vs normoalbuminuria) 1∙89 (1∙32;2∙70) <0∙001  2∙39 (1∙88;3∙02) <0∙001 
Systolic blood pressure (10 mmHg) 1∙08 (1∙03;1∙14) 0∙004  0∙90 (0∙86;0∙93) <0∙001 
HbA1c (10 mmol/mol) 1∙12 (1∙03;1∙20) 0∙005  1∙10 (1∙04;1∙15) <0∙001 
Smoking (vs no smoking ) 1∙27 (1∙00;1∙62) 0∙048  1∙88 (1∙63;2∙18) <0∙001 
Previous CVD event (vs no) 1∙35 (1∙05;1∙74) 0∙019  1∙93 (1∙65;2∙25) <0∙001 
Age (10 years), women -  2∙37 (2∙18;2∙59) <0∙001 
Age (10 years), men -  1∙92 (1∙78;2∙07) <0∙001 
ESKD: end-stage kidney disease; CVD: Cardiovascular disease;  






Figure 1 C-statistic for an end-stage kidney disease event within years of follow-up time in the derivation cohort (A) and 
in the validation cohorts (C), and p-value for test of adequate model fit in the derivation cohort (B) and in the validation 
cohorts (D). The dotted horizontal lines in (B) and (C) denotes the threshold for acceptable model calibration (acceptable 
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